Patents by Inventor Didrik Paus
Didrik Paus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240058811Abstract: Disclosed are processing cartridges with main cartridge section and actuating cartridge section, the main cartridge section has liquid reservoir chamber, liquid container, container piercing element and resilient container holding element, the actuating cartridge section can dock with the main cartridge section and comprises actuating member that interacts with the liquid container during docking; the liquid container, piercing element and container holding element are arranged in the liquid reservoir chamber, the liquid container is filled with suitable processing liquid and features pierceable dispensing side, and container piercing element faces the dispensing side; the liquid container is held in a position by the container holding element, dispensing side is separated from the container piercing element; and the actuating member can move the liquid container from the position to another position during docking of cartridge actuating section, and in the other position the dispensing side is pierced by conType: ApplicationFiled: November 30, 2021Publication date: February 22, 2024Applicant: SpinChip Diagnostics ASInventors: Sebastian STENMARK, Stig Morten BORCH, Torgeir HAMSUND, Erik L. MEYER, Rolf JAHREN, HÃ¥vard KRISTIANSEN, Odd Martin STAAL, Steven HILL, Didrik PAUS, Ole-Andreas KAVLI
-
Publication number: 20160208003Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: August 25, 2015Publication date: July 21, 2016Applicant: AFFITECH RESEARCH ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
-
Patent number: 9145461Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: April 25, 2013Date of Patent: September 29, 2015Assignee: Affitech Research ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
-
Patent number: 8822664Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: March 27, 2013Date of Patent: September 2, 2014Assignee: Affitech Research ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
-
Patent number: 8637017Abstract: Disclosed are antibodies that bind to Epithelial Cell Adhesion Molecule (EpCAM) and display certain advantages over known antibodies which bind to EpCAM, for example, the antibodies of the invention show good affinity, good cross-reactivity profiles and excellent ADCC and CDCC activity. Antibodies comprising specific heavy and light chain CDRs are disclosed. The invention thus relates to these antibodies and all uses thereof, in particular in the treatment of cancer. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer. Advantageous immunoconjugate compositions and methods using the new anti-EpCAM antibodies are also provided.Type: GrantFiled: June 9, 2010Date of Patent: January 28, 2014Assignee: Affitech Research ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus, Jenny Margareta Karlsson, Remko Albert Griep, Sergej Michailovic Kiprijanov
-
Publication number: 20130236535Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: April 25, 2013Publication date: September 12, 2013Applicant: AFFITECH RESEARCH ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
-
Patent number: 8461304Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: June 9, 2010Date of Patent: June 11, 2013Assignee: Affitech Research ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
-
Publication number: 20100310463Abstract: Disclosed are antibodies that bind to Epithelial Cell Adhesion Molecule (EpCAM) and display certain advantages over known antibodies which bind to EpCAM, for example, the antibodies of the invention show good affinity, good cross-reactivity profiles and excellent ADCC and CDCC activity. Antibodies comprising specific heavy and light chain CDRs are disclosed. The invention thus relates to these antibodies and all uses thereof, in particular in the treatment of cancer. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer. Advantageous immunoconjugate compositions and methods using the new anti-EpCAM antibodies are also provided.Type: ApplicationFiled: June 9, 2010Publication date: December 9, 2010Applicant: AFFITECH RESEARCH ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus, Jenny Margareta Karlsson, Remko Albert Griep, Sergej Michailovic Kiprijanov
-
Publication number: 20100310464Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: June 9, 2010Publication date: December 9, 2010Applicant: AFFITECH RESEARCH ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus